LA
AXDX

Lucus Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Lucus Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-8,000
Closed -$1.53M – 323
2014
Q4 		$1.53M Buy
+8,000
New +$1.71M 0.69% 14

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lucus Advisors's AXDX Position: Q1 2015 in Review

Lucus Advisors sold out of Accelerate Diagnostics (AXDX) in Q1 2015, closing a stake of 8,000 shares — an estimated $1.53M sold.

Lucus Advisors first reported a position in AXDX in Q4 2014 and held it in 1 quarter. The position peaked at $1.53M in Q4 2014. 75 funds tracked by Wall St. Rank hold AXDX as of Q1 2015.

  • Lucus Advisors reported no remaining Accelerate Diagnostics position as of Q1 2015 after selling out during the quarter.
  • Lucus Advisors sold 8,000 Accelerate Diagnostics shares in Q1 2015, an estimated $1.53M.
  • Lucus Advisors first reported a position in Accelerate Diagnostics in Q4 2014 and held it in 1 quarter.
  • Lucus Advisors's Accelerate Diagnostics position peaked at $1.53M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2015.

Based on Lucus Advisors's 13F filing for Q1 2015, filed 12 May 2015.